Autres langues Supernus Pharmaceuticals, Inc.

Actions

SUPN

US8684591089

Temps réel estimé Cboe BZX Autres places de cotation 20:42:48 23/04/2024			Varia. 5j.	Varia. 1 janv.
30,13 ^USD	+1,41 %		+1,94 %	+3,66 %

08/04	La demande de médicament expérimental de Supernus pour la pompe à apomorphine pour la maladie de Parkinson subit un revers de la part de la FDA ; les actions chutent avant la mise sur le marché	MT
08/04	Supernus Pharmaceuticals, Inc. annonce une mise à jour réglementaire pour le SPN-830	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN	20/04
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	08/04
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	08/04
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	08/04
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	08/04
Supernus Provides Regulatory Update for SPN-830	08/04
Supernus Provides Regulatory Update for SPN-830	08/04
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	25/03
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	21/03
Supernus to Participate in Two Upcoming Investor Conferences	06/03
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference	28/02
Supernus: Q4 Earnings Snapshot	28/02
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	27/02
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	27/02
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	27/02
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results	27/02
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results	27/02
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Supernus Pharmaceuticals, Inc. Announces Executive Changes	21/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Supernus Pharmaceuticals, Inc.

Actions

SUPN

US8684591089

Autres langues

Filtres